| Business Summary | | AXYS
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
focused
on
the
discovery,
design
and
development
of
therapeutic
small
molecules
that
address
significant
markets
with
major
unmet
medical
needs.
AXYS
collaborates
with
large
pharmaceutical
companies
in
discovering
therapeutics
for
chronic
diseases
for
which
there
are
large
markets.
Currently,
the
Company
has
significant
collaborations
with
Aventis
Pharmaceuticals
Product,
Inc.
(a
subsidiary
of
Aventis
S.A.),
Merck
&
Co.
and
Bayer
A.G.
The
Company
also
selectively
focuses
its
own
resources
on
discovering
and
developing
therapeutics
for
the
treatment
of
various
types
of
cancer
and
other
specialty
market
therapeutics.
The
Company
has
on-going
programs
in
the
treatment
of
autoimmune,
inflammatory
diseases,
and
cancers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AXPH
is
a
biopharmaceutical
company
focused
on
the
discovery,
development
and
commercialization
of
therapeutic
small
molecules.
For
the
six
months
ended
6/30/01,
revenues
increased
33%
to
$3.9
million.
Net
loss
from
continuing
operations
before
accounting
change
increased
85%
to
$32.4
million.
Revenues
reflect
research
collaborations
with
Merck
and
Aventis.
Higher
loss
reflects
a
$9.4
million
loss
in
the
investment
in
DPI
and
the
write-off
of
the
investment
in
Akkadix. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| John Walker, 51 Chairman | $665K | Paul Hastings, 40 Pres,
CEO, Director | -- | David Riggs Sr. VP, CFO | -- | William Newell, 42 Sr.
VP, Sec. | 244K | Daniel Hoth, M.D., 54 Sr.
VP, CMO | 157K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|